Journal Article

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG

Pan, Yunqian, Kharbanda, Anupreet, Yan, Yuqian, Wang, Dejie, He, Yundong, Li, Hong‐yu, Yan, Wei, Shao, Jingwei, Huang, Haojie, Ding, Donglin

2021

Overview

DNA‐binding proteins, including transcription factors (TFs), play essential roles in various cellular processes and pathogenesis of diseases, deeming to be potential therapeutic targets. However, these proteins are generally considered undruggable as they lack an enzymatic catalytic site or a ligand‐binding pocket. Proteolysis‐targeting chimera (PROTAC) technology has been developed by engineering a bifunctional molecule chimera to bring a protein of interest (POI) to the proximity of an E3 ubiquitin ligase, thus inducing the ubiquitination of POI and further degradation through the proteasome pathway. Here, the development of oligonucleotide‐based PROTAC (O'PROTACs), a class of noncanonical PROTACs in which a TF‐recognizing double‐stranded oligonucleotide is incorporated as a binding moiety of POI is reported. It is demonstrated that O'PROTACs of lymphoid enhancer‐binding factor 1 (LEF1) and ETS‐related gene (ERG), two highly cancer‐related transcription factors, successfully promote degradation of these proteins, impede their transcriptional activity, and inhibit cancer cell growth in vitro and in vivo. The programmable nature of O'PROTACs indicates that this approach is also applicable to destruct other TFs. O'PROTACs not only can serve as a research tool but also can be harnessed as a therapeutic arsenal to target DNA binding proteins for effective treatment of diseases such as cancer. DNA binding proteins including transcription factors remain as challenging targets in drug discovery. oligonucleotide‐based proteolysis‐targeting chimeras (O'PROTACs), which employ unique DNA sequences as natural “ligand” of targeting proteins, are developed to effectively destruct lymphoid enhancer‐binding factor 1 (LEF1) and ETS‐related gene (ERG) and inhibit prostate cancer cell growth. O'PROTAC represents an attractive approach for treatment of diseases including cancer.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• Subject: cancer / Cancer therapies / Cell growth / DNA-Binding Proteins - genetics / Gene expression / Humans / Ligands / Lymphoid Enhancer-Binding Factor 1 - genetics / Neoplasms - genetics / Neoplasms - therapy / Oligonucleotides - genetics / Oligonucleotides - pharmacology / oligonucleotide‐based proteolysis‐targeting chimera / Prostate cancer / Proteasome Endopeptidase Complex - genetics / protein degradation / Proteins / Proteolysis - drug effects / transcription factor / Transcription factors / Transcriptional Regulator ERG - genetics / Ubiquitin-Protein Ligases - genetics